Cannabis has many potential benefits for various medical conditions, but delivering it in a consistent and effective way can be challenging. That’s why Zelira Therapeutics, a global leader in the research, development and commercialization of clinically validated cannabinoid medicines, has developed a technology to make cannabinoid-based oral medications a reality.
The technology, called ZYRAYDI™, traps cannabis distillate in a free-flowing powder matrix that can be used to create pharmaceutical-grade dosage forms like capsules and tablets. This allows for precise dosing, improved bioavailability and enhanced stability of the active ingredients. Using this technology, Zelira has created Zenivol™, the world’s first and only clinically validated, cannabis-based sleep medication that has achieved regulatory approval in Germany and Australia.
The company is not only focused on creating cannabinoid-based medicines for specific conditions like insomnia, autism and chronic pain, but also on expanding its product portfolio to other areas of health and wellness. As an individual with insomnia, I am quite excited about it. One of its latest ventures is the launch of cannabinoid-based oral care products in partnership with SprinJene®, a natural oral care company. The first oral care product will be a proprietary toothpaste formulation containing cannabinoids including CBD, which is expected to launch by the end of the year in the US.
Zelira Therapeutics is committed to building patient and doctor confidence in its medicines with an ethical, evidence-based approach, applying world-class science and conducting clinical trials. With its innovative technology and diverse product range, Zelira is reimagining healthcare for millions of people underserved by current treatments.